Priced Oct 8, 2026 · range was $11–$13 · latest SEC filing Nov 4, 2026.
Pinch-zoom for details.
Clinical-stage drug developer focused on high blood pressure; its candidate RTN-001 is a once-daily oral PDE-5 inhibitor.
Fiscal year
1st half
Fiscal year
1st half
| $ | FY2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Operating result | (2.28M) | (6.88M) | −202% | (2.11M) | (7.79M) | −269% |
| Net result | (1.91M) | (6.30M) | −230% | (1.89M) | (7.53M) | −299% |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Operating result | (2.28M) | (6.88M) | −202% |
| Net result | (1.91M) | (6.30M) | −230% |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Operating result | (2.11M) | (7.79M) | −269% |
| Net result | (1.89M) | (7.53M) | −299% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing's own risk-factor headings, shortened.
The filing's own strategy headings, shortened.
Source: Retension Pharmaceuticals, Inc.'s Form 424B4, filed with the SEC on Oct 9, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back